💉FOLFOX/Xelox + beva vs. 5FU/cape +beva in first line treatment of metastatic CRC in older patients Journal of Clinical Oncology ➡️Median age 80 and 79 ❌No difference in PFS, 10 vs 9.4 mo. ❌No difference in OS, 19.7 vs 21.3 mo. ❌grade ≥3 AEs 69% vs. 52% ❗️~65% left sided and ~36% RAS WT

Thrilled to share our latest article just published in Annals of Oncology regarding the role of liquid biopsy CGP in patients with RAS/BRAF wt MSS metastatic colorectal cancer enrolled in the CAPRI-2 GOIM study IEO ESMO - Eur. Oncology annalsofoncology.org/article/S0923-…

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade | Nature Communications nature.com/articles/s4146…

New in press: Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial. Davide Ciardiello G Curigliano MD PhD doi.org/10.1016/j.anno…

Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic #ColorectalCancer Is Transient: brnw.ch/21wMhv7 Jonathan Loree #crcsm

Just published in Oncoimnunology 📢 "Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab in patients with advanced cutaneous squamous cell carcinoma" VNardone Stefania Napolitano Giuseppe Argenziano tandfonline.com/doi/full/10.10…

Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis 💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS ❗️An analysis based on MSI status and T4a/b was not performed

Omission of 5-FU Bolus From Multidrug Regimens 🔍Retrospective study with ~12,000 pts in GI cancer 💥Omitting 5-FU bolus had no negative impact on survival (FOLFOX, FOLFIRI, FOLFIRINOX) 💥Associated with a significant reduction in toxicity jnccn.org/view/journals/…

🚨Hot of the press - Pleased to share our paper 👉🏼just before @esmo #ESMO24 👉🏼⭐️Huge congratulations to our early phase 1 clinical trials team Sarah Cannon Docs for the publication Journal of Clinical Oncology ASCO 👉🏼 First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate

❓LC-CRT vs. SC-RT for Rectal Cancer Organ Preservation❓ MSKCC SOC: LC-CRT TNT, during COVID shifted to SC-RT Study demonstrated: 🟢🟰cCR rates (~ 40%) 🟢🟰 OS and DFS 🧐 ⬇️Regrowth ⬆️Organ Preservation w/ LC-CRT 🔥Suggests LC-CRT preferred for NOM German AIO-18 to clarify

☀️Ready for #ESMO24 Day-2 🍀 Full of exciting scientific data! ESMO - Eur. Oncology GI: ✅Upper GI proffered-2 ✅Precision med in NEN ✅ Novel targeted treatments in GEJ and pancreatic cancer ✅Young onset CRC ✅CRC cancer 3L and beyond ✅Lower GI, mini oral ✅Targeted treatments in BTC

‼️‼️Is it the time of precision oncology in NENs 🦓🦓🦓? 📣 Amazing letture on the molecular landscape of NENs 📣 A look to the future with the value of liquid biopsy 📣 New amazing nuclear tracers incoming 📣 Next step forward in systemic therapy ESMO - Eur. Oncology OncoDaily antichrist

⚡️Lower GI- Proffered paper (Day-3) #ESMO24 ESMO - Eur. Oncology ➡️ LEANOX trial ➡️Lean body mass based dosage of oxaliplatin in adjuvant of CRC ✅ peripheral neurotoxicity ⬇️ ✅No effect on RFS and OS OncoAlert #medx #cancer #oncology

See you all at the poster area this Monday! #ESMO24 👇👇👇👇

⚡️Upper GI- Mini oral (Day-4) #ESMO24 ESMO - Eur. Oncology ➡️ Response to neoadjuvant FLOT to decide adjuvant FLOT? ✅Only partial responders benefit from adjuvant treatment ❗️ ❗️Prospective clinical trials is needed OncoAlert OncLive.com #medx #cancer #oncology

Presented at #ESMO24: The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemotherapy alone. Full correspondence: nej.md/3ML9dtK

#ESMO24 ESMO - Eur. Oncology CABINET - ph3 cabozantinib vs placebo in pre-treated advanced #Neuroendocrine NETs Alliance for Clinical Trials in Oncology NEJM Jennifer Chan 📌results presented by BICR for epNET and pNET ➡️ORR 5% vs 0 in epNET, 19% vs 0 in pNET ➡️PFS HR 0.38 in epNET, HR 0.23 in pNET OncoAlert OncologyEducation

🔥Presidential Symposium III: Eyes to the future🔥 TNT with non-operative management for pMMR LARC #ESMO24 🔎First results of NO-CUT trial 👉cCR 26% 👉DRFS30 97%, NOM 85% 👉ctDNA+ predicts recurrence 🧐Next step to select pts for NOM ESMO - Eur. Oncology #ESMOAmbassadors

⁦IEO⁩ Ranked 9th best cancer center in the world: Innovation and research to impact on cancer patients outcome ⁦ESMO - Eur. Oncology⁩ ⁦ASCO⁩ ⁦AACR⁩ newsweek.com/rankings/world…

Liver transplantation + CTx vs CTx in unresectable CRC liver metastases 🔎TransMet randomised trial The Lancet doi.org/10.1016/S0140-… 👉5-yr OS: 56.6 vs 12.6% 👉Recurrence after LTx: 72% 🧐Impressive study, impressive results ❗️LTx valid option in highly selected pts ESMO - Eur. Oncology